Abbreviations {#nomen0010}
=============

α-GI

:   alpha-glucosidase inhibitor

ASBT

:   apical sodium-dependent bile acid transporter

CYP7A1

:   cholesterol 7α-hydroxylase

CYP8B1

:   sterol 12α-hydroxylase

FGF

:   fibroblast growth factor

FXR

:   farnesoid X receptor

HNF

:   hepatocyte nuclear factor

IBABP

:   ileal bile acid binding protein

LXR

:   liver X receptor

MRP

:   multidrug resistance protein

NTCP

:   Na(+)-taurocholate co-transporting polypeptide

OATP

:   organic anion transporting polypeptide

OST

:   organic solute and steroid transporter

PGC

:   peroxisome proliferator-activated receptor-γ coactivator

SHP

:   small heterodimer partner

KLB

:   β-klotho

ABCG

:   ATP-binding cassette transporter G

NPC1L1

:   Niemann-Pick C1-Like 1

1. Introduction {#sec1}
===============

Bile acids (BAs) have been shown to contribute to energy homeostasis and glycolysis \[[@bib1],[@bib2]\]. We have recently reported that miglitol, an alpha-glucosidase inhibitor (αGI), influences fecal and blood BA concentrations, and ameliorates insulin resistance along with obesity in mice \[[@bib3]\]. The mechanisms by which miglitol affects BA metabolism, however, remained to be clarified.

BA concentrations are strictly regulated by the feed-back mechanisms mainly via farnesoid X receptor (FXR)-small heterodimer partner (SHP) pathway along with numerous receptors, enzymes and transporters in the liver and gut \[[@bib4],[@bib5]\]. On the other hand, various factors other than BAs may influence these molecules. For example, cholesterol 7α-hydroxylase (CYP7A1), a rate-limiting enzyme of BA synthesis, is known to be regulated by FXR-independent mechanisms \[[@bib6],[@bib7]\].

Present study aimed to clarify the mechanism(s) for miglitol-induced BA hypersecretion. We conclude that miglitol upregulates hepatic CYP7A1 possibly via increased short-chain fatty acid production resulting from alterations in gut microbiome.

2. Materials and methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All procedures were conducted according to the Guidelines for the Care and Use of Laboratory Animals of Sanwa Kagaku Kenkyusho (SKK). Five-week-old male Nagoya-Shibata-Yasuda (NSY) mice (Hoshino Laboratory Animals, Ibaragi, Japan), known as a spontaneous-onset obese type 2 diabetes model \[[@bib8]\], were fed with normal chow (n = 10) or a high-fat diet (HFD) (Casein, 23.6%; Sucrose, 20.4%; lard, 20.93% in composition; Oriental Yeast, Tokyo, Japan) (n = 10) that were free from or mixed with 0.08% miglitol for 4 weeks.

2.2. Measurement of total bile acid concentrations in feces {#sec2.2}
-----------------------------------------------------------

Feces were collected over a period of 24 h two days prior to the sacrifice and were frozen-dried and powdered followed by extraction twice with 90% ethanol at 65 °C for 1 h. After centrifugation, the supernatants were dried under a nitrogen stream and re-dissolved in 90% ethanol. Total bile acids were determined using the Total bile acid-test kit (Wako, Osaka, Japan).

2.3. Gene expression analysis {#sec2.3}
-----------------------------

Mice were sacrificed at 4 weeks after treatment, and the liver and the distal ileum were immediately removed and frozen. Total RNA was extracted from the frozen tissues and cDNA was synthesized using High Capacity cDNA Reverse Transcription® kit (Applied Biosystems, Tokyo, Japan). The mRNA of BA-related genes was quantified by real-time PCR using TaqMan probes with TATA box binding protein as an endogenous control. The primers and probes for these genes were purchased from Applied Biosystems.

2.4. Determination of CYP7A1 activity {#sec2.4}
-------------------------------------

The livers were homogenized in 100 mM Na~3~PO~4~, pH 7.2, containing 100 mM sucrose, 50 mM KCl, 50 mM NaF, 5 mM EGTA, 3 mDTT, 1 mM EDTA, 1 mM PMSF and 100 μM leupeptin, and then centrifuged twice at 10,000 g for 10 min. The supernatant was centrifuged at 38,000 rpm for 60 min and the pellets were mixed with 0.1 M Na~4~P~2~O~7~, 50 mM NaF, and 1 mM EDTA. The specific activity of CYP7A1 was determined using an HPLC assay procedure as described previously \[[@bib9]\].

2.5. Western blot analysis {#sec2.5}
--------------------------

Proteins extracted from the liver microsomal fraction were loaded on SDS-PAGE and then transferred onto PVDF membranes. The membranes were blocked, incubated with primary antibodies against CYP7A1 and calnexin, and washed. The membranes were then incubated with HRP-conjugated secondary antibodies and washed, followed by detection with ECL Plus® (GE Healthcare, Tokyo, Japan).

2.6. Determination of gut mirobiome and SCFA concentrations {#sec2.6}
-----------------------------------------------------------

Cecal samples were collected at the sacrifice and immediately frozen. Microbiome was measured using terminal restriction fragment-length polymorphism (T-RFLP) analysis as previously described \[[@bib10]\]. SCFA concentrations were quantified by HPLC using a post column reaction with a detector, tandemly arranged two columns and a guard column as mentioned previously \[[@bib11]\].

2.7. Statistical analyses {#sec2.7}
-------------------------

Data were analysed using analysis of variance (ANOVA) with post-hoc comparisons.

3. Results {#sec3}
==========

3.1. Effects of miglitol on genes involved in BA metabolism {#sec3.1}
-----------------------------------------------------------

Miglitol enhanced BA excretion to feces in HFD-fed mice ([Fig. 1](#fig1){ref-type="fig"}A) and tended to suppress body weight ([Fig. 1](#fig1){ref-type="fig"}B). The mRNA expression of hepatic CYP7A1 was clearly increased by miglitol ([Fig. 1](#fig1){ref-type="fig"}C), whereas miglitol did not alter the mRNA expression of SHP, FXR and other genes relating to hepatic BA production. The expression of Na(+)-taurocholate co-transporting polypeptide (NTCP) was mildly reduced whereas other hepatic BA transporters were unchanged. Fibroblast growth factor receptor (FGFR) 4 and β-klotho (KLB) expression was not altered by the agent ([Fig. 1](#fig1){ref-type="fig"}C).Fig. 1Effects of miglitol on bile acid-related gene expression in HFD-fed NSY mice treated (black bars) or untreated (white bars) with miglitol for 4 weeks. (A) Fecal bile acid levels, (B) BW changes, (C) The mRNA expression of hepatic genes involved in bile acid production and transport, (D and E) Protein expression and enzyme activity of hepatic CYP7A1, (F) The mRNA levels of ileal genes involved in bile acid regulation. \*p \< 0.05, \*\*p \< 0.01 and \*\*\*p \< 0.001 vs. control, Error bars express SE (n = 10 in A, B, C, E, F and n = 5 in D).Fig. 1

In accordance with mRNA expression, miglitol significantly enhanced the protein expression as well as the activity of hepatic CYP7A1 ([Fig. 1](#fig1){ref-type="fig"}D and E).

In the intestine, miglitol increased the mRNA expression of SHP and suppressed that of FXR ([Fig. 1](#fig1){ref-type="fig"}F). The mRNA expression of apical sodium-dependent BA transporter (ASBT), a primary BA transporter in enterocytes, was significantly decreased by miglitol and the mean expression of other BA transporters was also lowered. FGF15 mRNA was not altered by the agent. Miglitol significantly suppressed ATP-binding cassette transporter G5 and G8 (ABCG5/8) expression in the intestine, but not in the liver.

3.2. Alteration of gut microbiome by miglitol {#sec3.2}
---------------------------------------------

Miglitol markedly reduced the prevalence of prevotella and suppressed clostridium cluster XVIII ([Fig. 2](#fig2){ref-type="fig"}A). In contrast, the prevalence of clostridium cluster XIV and bifidobacterium was significantly increased by miglitol and lactobacillales was prone to increase. Miglitol did not affect the total cecal bacterial counts (10.44 ± 0.05 vs. 10.46 ± 0.05 log/g).Fig. 2Alterations of gut microbiome and short-chain fatty acid (SCFA) levels by miglitol in HFD-fed NSY mice treated (black bars) or untreated (white bars) with miglitol for 4 weeks. (A) Cecal microbiome, (B) SCFA levels in cecal feces, (C) Correlation between fecal SCFA levels and hepatic CYP7A1 mRNA levels. r = 0.549, p = 0.011 in total observation (a solid line), r = 0.42, p = 0.20 in the control group (a dashed line) and r = 0.10, p = 0.79 in the miglitol group, (D) Plasma total cholesterol and triglycerides, and (E) Tentative explanation for mechanisms by which miglitol affects BA metabolism. \*p \< 0.05, \*\*p \< 0.01 and\*\*\*p \< 0.001 vs. an untreated group, respectively. Error bars express SE (n = 10).Fig. 2

3.3. Fecal SCFA {#sec3.3}
---------------

Miglitol significantly increased formic and n-butyric acids in feces of HFD-fed mice ([Fig. 2](#fig2){ref-type="fig"}B). While saccinate was decreased by miglitol, the total amount of fecal SCFA was significantly increased by the agent.

Between hepatic CYP7A1 mRNA levels and fecal SCFA concentrations, there was a significant positive correlation in total mice and a tendency for correlation in control mice ([Fig. 2](#fig2){ref-type="fig"}C).

3.4. Serum lipids {#sec3.4}
-----------------

Miglitol did not show significant effect on serum cholesterol or triglyceride levels ([Fig. 2](#fig2){ref-type="fig"}D).

4. Discussion {#sec4}
=============

In present study, miglitol clearly enhanced the expression and activity of hepatic CYP7A1 and suppressed ileal ASBT expression. These results suggest that the agent elevates hepatic BA production and its secretion to gut, which in turn suppress BA absorption by transporters in the ileum. The data seems to account for our present and previous \[[@bib12]\] data that the agent enhances fecal BA secretion.

It is intriguing that the miglitol effects appear inconsistent in some points with known feedback regulation of BAs. BAs are well demonstrated to stimulate FXR and subsequently to induce SHP, which results in the suppression of hepatic CYP7A1 \[[@bib4]\] and ileal BA transporters. The BA activation of ileal FXR-SHP pathway augments humoral factors FGF15/19 that suppress hepatic CYP7A1 via FGFR1/4 with β-klotho \[[@bib12]\]. Our present data showed that FXR mRNA was not altered in the liver and lowered in the intestine, and ileal FGF15 and hepatic FGFR4 along with KLB were not upregulated. Because the transcriptional activity of FXR is independent of its mRNA expression \[[@bib13]\], this may give explanation for the discrepancy between the FXR expression and its downstream molecules. Nevertheless, it ispuzzled that FGF15-FGFR/KLB axis was not upregulated under the condition where ASBT expression was clearly suppressed.

Several factors other than BAs have been reported to regulate hepatic CYP7A1.

SCFAs such as acetate, propionate and butylate have been observed to upregulate liver CYP7A1 expression in vivo \[[@bib14]\] and in vitro \[[@bib15]\]. In present study, miglitol altered gut microbiome and SCFA concentrations, in accordance with previous papers where an αGI acarbose was reported to affect gut bacterial flora and SCFA \[[@bib16],[@bib17]\] as well as plasma SCFA \[[@bib18],[@bib19]\]. This is probably because the agent delays saccharide absorption in the upper intestine and subsequently increase saccharide concentrations in the lower intestine, which alters fermentation and intestinal environment. These findings may indicate that the miglitol effect on CYP7A1 is attributable in part to SCFA elevation accompanying gut microbial changes, and the observed correlation between fecal SCFA concentrations and hepatic CYP7A1 expression possibly supports the hypothesis.

Cholesterol levels may also affect CYP7A1 via LXR \[[@bib4],[@bib5]\]. Although SCFA have been reported to lower plasma cholesterol \[[@bib15]\], we failed to observe reduction in cholesterol levels by miglitol. Decreased intestine ABCG5/8 expression and resultant reduction in sterol excretion possibly intertwines the cholesterol metabolism.

In addition to above mechanisms, our previous study \[[@bib3]\] has demonstrated that miglitol induces deiodenase 2, an enzyme converting thyroid hormone T4 to T3, in brown adipose tissues. Because T3 is known to increase CYP7A1 activity \[[@bib6],[@bib7],[@bib20]\], this effect possibly mediates to some degree the miglitol enhancement of CYP7A1.

Limitation of our study is the lack of direct evidence for the cause-effect relationship between SCFAs and CYP7A1. The mechanism for non-activation of FGF15-FGFR/KLB pathway under treatment with miglitol also remains to be clarified.

In conclusion, an αGI miglitol affects BA metabolism via upregulation of hepatic CYP7A1, and the alterations in gut microbiome along with SCFA production may underlie the effect. Given the fact that BA metabolism is involved in the energy homeostasis and nutrient metabolism, the effects of αGI appear worth further investigation.
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